Fas receptor (CD95) & fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma

Indian Journal of Medical Research

Volumn 134, Issue 7, 2011, Pages 54-60

  Das, Satya N ^a   Khare, Pratima ^a   Singh, Manoj K ^a   Sharma, Suresh C ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

DNA ploidy; Fas; Fasl; Oral cancer

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRAORAL SQUAMOUS CELL CARCINOMA; LYMPH NODE; MALE; MOUTH; MOUTH CARCINOMA; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TOBACCO; TUMOR VOLUME;

EID: 80054723936     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995; 154: 1239-45.
2. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
3. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT 1/FADD - interacting protease, in Fas/APO1-and TNF-receptor-induced cell death. Cell 1996; 85: 803-15.
4. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000; 78: 312-25.
5. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma - cell expression of Fas (Apo-1/ CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-6.
6. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
7. Reichmann E. The biological role of the Fas/FasL system during tumour formation and progression. Semin Cancer Biol 2002; 12: 309-15.
8. Biennial Report, National Cancer Registry Programme 1988- 89. New Delhi: Indian Council of Medical Research, July 1992.
9. Khanna NN, Srivastava PK, Khanna S, Das SN: Intensive combination chemotherapy for cancer of the oral cavity. Cancer 1983; 52: 790-3.
10. Sawhney M, Mathew M, Valarmathi MT, Das SN. Age related changes in Fas (CD95) and Fas ligand gene expression and cytokine profiles in healthy Indians. Asian Pac J Allergy Immunol 2006; 24: 47-56.
11. Manchanda P, Sharma SC, Das SN. Differential regulation of IL-2 and IL-4 in patients with tobacco related oral squamous cell carcinoma. Oral Dis 2006; 12: 455-62.
12. Das SN, Khare P, Patil A, Pandey RM, Singh MK, Shukla NK. Association of DNA pattern of metastatic lymph node with disease free survival in patients with intraoral squamous cell carcinoma. Indian J Med Res 2005; 122: 216-23.
13. American Joint Committee on Cancer. Manual for staging of cancer, 3rd ed. Philadelphia: J.B. Lippincott; 1988. p. 27-32.
14. Hood DL, Petras RE, Edinger M, Fazio V, Tubbs RR. Deoxyribonucleic acid ploidy and cell cycle analysis of colorectal carcinoma by flow cytometry. A prospective study of 137 cases using fresh whole cell suspensions. Am J Clin Pathol 1990; 93: 615-20.
15. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2015-26.
16. Mullauer L, Mosberger I, Grusch M, Rudas M, Chott A. Fas ligand is expressed in normal breast epithelial cells and is frequently up regulated in breast cancer. J Pathol 2000; 190: 20-30.
17. Fukuzawa K, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, et al. Expression of Fas/Fas Ligand and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol 2001; 36: 681-8.
18. Shimoyama M, Kanda T, Liu L, Koyama Y, Suda T, Sakai Y, et al. Expression of Fas ligand is an early event in colorectal carcinogenesis. J Surg Oncol 2001; 76: 63-8; discussion 69.
19. Abdulkarim B, Sabri S, Deutsch E, Vaganay S, Marangoni E, Vainchenker W, et al. Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells. Int J Cancer 2000; 86: 229-37.
20. Sundelin K, Jadner M, Norberg-Spaak L, Davidsson A, Hellquist HB. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 1997; 33: 1860-4.
21. Younes M, Schwartz MR, Finnie D, Younes A. Over expression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrette's metaplasia of the esophagus. Hum Pathol 1999; 30: 1309-13.
22. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and downregulation of Fas expression by human esophageal cancer. Cancer Res 1998; 58: 2057-62.
23. Loro LL, Vintermyr OK, Johannessen AC, Liavaag PG, Jonsson R. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 1999; 28: 82-7.
24. Huges SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997; 57: 5571-8.
25. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 1998; 101: 1102-10.
26. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-12.
27. Bennett MW, O'Connell J, O' Sullivan GC, Brady C, Roche D, Collins JK, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-75.
28. Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999; 285: 898-900.
29. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-62.
30. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005; 11: 1010-20.
31. Whiteside TL. The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 2007; 36: 25-46.
32. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-64.
33. Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 2009; 31: 371-80.
34. + responder cells by Fas -mediated apoptosis. J Immunol 2009; 182: 1469-80.